Odds ratios showing the likelihood of isolates being methicillin-resistant in <i>Staphylococcus pseudintermedius</i> isolates from dogs in Australia for different combinations of site of infection in the host and exposure of the host to prior antimicrobial treatment.

<p>Odds ratios showing the likelihood of isolates being methicillin-resistant in <i>Staphylococcus pseudintermedius</i> isolates from dogs in Australia for different combinations of site of infection in the host and exposure of the host to prior antimicrobial treatment.</p

Resistance profile per antimicrobial class found in clinical <i>Staphylococcus aureus</i> isolates from horses, dogs and cats in Australia (2013–2014)

<p>Resistance profile per antimicrobial class found in clinical <i>Staphylococcus aureus</i> isolates from horses, dogs and cats in Australia (2013–2014)</p

Antimicrobial agents and MIC breakpoints (μg/mL) used in this study based on CLSI VET01S and ECOFFs criteria.

<p>Antimicrobial agents and MIC breakpoints (μg/mL) used in this study based on CLSI VET01S and ECOFFs criteria.</p

Univariate analysis of risk-factor variables from <i>Staphylococcus pseudintermedius</i> isolates from dogs in Australia (n = 555).

<p>Odds ratios define the risk of isolates being classified as methicillin-resistant strains.</p

Resistance profile per antimicrobial class found in clinical <i>Staphylococcus pseudintermedius</i> isolates in Australia (2013–2014)

<p>Resistance profile per antimicrobial class found in clinical <i>Staphylococcus pseudintermedius</i> isolates in Australia (2013–2014)</p

MIC distribution and frequency of resistance (%R) among clinical <i>Staphylococcus pseudintermedius</i> isolated from dogs (n = 616) and cats (n = 13) in Australia^a.

<p>MIC distribution and frequency of resistance (%R) among clinical <i>Staphylococcus pseudintermedius</i> isolated from dogs (n = 616) and cats (n = 13) in Australia<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0176379#t002fn001" target="_blank">^a</a>.</p

MIC distribution and frequency of resistance (%R) among clinical <i>Staphylococcus aureus</i> isolated from horses (n = 53), dogs (n = 47), and cats (n = 17) in Australia^b.

<p>MIC distribution and frequency of resistance (%R) among clinical <i>Staphylococcus aureus</i> isolated from horses (n = 53), dogs (n = 47), and cats (n = 17) in Australia<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0176379#t003fn002" target="_blank">^b</a>.</p

Biophotonic imaging of burn wounds.

<p>(<b>A</b>) Timeline of scald injury experiments. (<b>B</b>) Dorsal images of representative BALB/c mice challenged with approx. 1 × 10⁷ CFU of bioluminescent <i>S</i>. <i>aureus</i> ATCC 12600 (Xen29). Mice were subjected to bioluminescent imaging on IVIS Lumina XRMS Series III system at the indicated times. (<b>C</b>), Quantification of photon intensities of bacterial burden showing significant reduction in photon intensities in mupirocin-treated mice. Total flux (means±SEM photons/s; n = 6 mice). *<i>p</i><0.05; **<i>p</i><0.01; multiple <i>t</i>-tests). (<b>D</b>), Total bacterial counts from tissues of control, infected but not treated, and infected + mupirocin-treated mice at the conclusion of the experiment, showing strong correlation with total photon intensities obtained from each treatment group.----denotes limit of detection; ^_____ denotes geometric mean counts.</p

Luminescence signal comparison between groups of CD1 mice challenged IP with <i>S</i>. <i>aureus</i> ATCC 12600 (Xen29).

<p>(<b>A</b>), Quantification of photon intensities on a Xenogen IVIS Lumina XRMS Series III live animal biophotonic imaging system, showing significant reduction in photon intensities in daptomycin-treated mice. Total flux (means±SEM photons/s; n = 6 mice). **<i>p</i><0.01; multiple <i>t</i>-tests). (<b>B</b>), Survival times for CD1 male mice (n = 6) challenged IP with approx. 2.5 × 10⁷ CFU of bioluminescent <i>S</i>. <i>aureus</i> Xen29 and administered the drug vehicle only or daptomycin (6 mg/kg) IP at 2 and 6 h post-infection. Differences in median survival times (time to moribund) for mice between groups were analyzed by the log-rank (Mantel-Cox) tests. ***, <i>P</i><0.001. (<b>C</b>), Total bacterial counts from blood of control and infected + daptomycin-treated mice at 2, 4 and 6 h post-infection.----denotes limit of detection; ^_____ denotes geometric mean counts.</p

Biophotonic ventral and dorsal images of 2 representative CD1 male mice challenged IP with approx.

<p><b>2.5 × 10⁷ CFU of bioluminescent <i>S</i>. <i>aureus</i> ATCC 12600 (Xen29) and then administered the drug vehicle only or daptomycin IP at 2 and 6 h post-infection</b>. Mice were subjected to bioluminescent imaging on IVIS Lumina XRMS Series III system at the indicated times.</p